Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834085 | 0.94 | MAPT (0.50) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL5952479 | 0.92 | POLB (0.52) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL11379383 | 0.92 | POLB (0.52) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL11057069 | 0.90 | MAPT (0.50) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL14659288 | 0.86 | TSHR (0.50) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL2880608 | 0.85 | ALDH1A1 (0.50) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL12658952 | 0.84 | SNCA (0.50) | POLBHTTMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL13375170 | 0.83 | MAPT (0.45) | POLBHTTMAPTMEN1KMT2A | |
| SCHEMBL3344589 | 0.83 | MAPT (0.52) | POLBMAPTMEN1KMT2AMCL1 | |
| SCHEMBL2554501 | 0.82 | TSHR (0.50) | POLBHTTMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750335-B2 | NUCLEOSIDE FOR USE IN THE GENERATION OF PREFERENTIAL OLIGONUCEOTIDES | NIGU CHEMIE GMBH (DE) | 2004-06-15 | — | — | US | disclosed |
| EP-1224198-B1 | NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTING GROUPS | NIGU CHEMIE GMBH (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020146737-A1 | Nucleoside derivatives with photolabile protective groups | NIGU CHEMIE GMBH (DE) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146737-A1 | Nucleoside derivatives with photolabile protective groups | XRN2, XPA, NSUN2 | POLB 47/4885HTT 1439/4885MAPT 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.